Leaders in Pharmaceutical Business Intelligence (LPBI) Group

​

Dear Colleague:

Recognizing that almost 40 percent of those who responded to the strategic planning survey underpinning the plan did not agree that “it is inevitable that all doctors will someday practice personalized medicine [because] the science and technology will demand it,” the Coalition has outlined robust efforts to encourage and nurture medical progress through education, advocacy, and evidence development.On behalf of the Personalized Medicine Coalition (PMC), I am pleased to share PMC’s Strategic Plan for 2019.

Unless payers, providers, patients, and policymakers are aware of personalized medicine, it will be harder to increase research funding and propose smart public policies that encourage integrating diagnostics into therapeutic decisions.

And unless we develop the evidence base necessary to demonstrate the clinical and economic value of personalized medicine, those decision-makers are not going to embrace it, and, in fact, may propose policies, like “step therapy” — paying for what costs least first — that fly in the face of the principles of personalized medicine.

In short, in keeping with the scientific and technological progress of recent years, we need to redouble our efforts to deliver the promise of personalized medicine — better clinical outcomes and more efficient health systems. The stakes are very high.

We welcome your participation in PMC this year. Without it, progress will be much slower than any of us would like.

Please contact PMC Membership & Development Director Kayla Smith at ksmith@personalizedmedicinecoalition.org with questions about how to get involved with any of the projects listed in the plan.

Sincerely yours,

Edward Abrahams

President